A phase I, open-label, multicenteir study to evaluate the safety and activity of rituximab in adults with relapsing-remitting multiple sclerosis (RRMS)

被引：0
作者：
Bar-Or, Amit
Calabresi, Peter
Arnold, Douglas
Markowitz, Clyde
Shafer, Stuart
Kasper, Lloyd
Waubant, Emmanuelle
Gazda, Suzanne
Fox, Robert
Sarkar, Neena
Panzara, Michael
Smith, Craig
机构：
来源：
NEUROLOGY | 2007年 / 68卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：A84 / A84
页数：1
相关论文
共 50 条
  • [41] Long-term (up to 26 years), open-label, compassionate use study of glatiramer acetate in relapsing-remitting multiple sclerosis
    Miller, A
    Spada, V
    Beerkircher, D
    Kreitman, RR
    Kadosh, S
    MULTIPLE SCLEROSIS JOURNAL, 2005, 11 : S84 - S84
  • [42] A non-inferiority study of rituximab versus ocrelizumab in relapsing-remitting multiple sclerosis
    Roos, I.
    Hughes, S.
    MacDonnell, G.
    Boz, C.
    Alroughani, R.
    Ozakbas, S.
    Buzzard, K.
    Skibina, O.
    Van der Walt, A.
    Butzkueven, H.
    Lechner-Scott, J.
    Kuhle, J.
    Terzi, M.
    Laureys, G.
    Van Hijfte, L.
    John, N.
    Grammond, P.
    Grand'Maison, F.
    Soysal, A.
    Sellebjerg, F.
    Gray, O.
    Magyari, M.
    Kalincik, T.
    Msbase and Danish Sclerosis Registry Study Grp
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 951 - 953
  • [43] Review Of The Safety, Efficacy And Tolerability Of Fingolimod In The Treatment Of Pediatric Patients With Relapsing-Remitting Forms Of Multiple Sclerosis (RRMS)
    Feng, Jenny
    Rensel, Mary
    PEDIATRIC HEALTH MEDICINE AND THERAPEUTICS, 2019, 10 : 141 - 146
  • [44] Phase I study of oval recombinant ovine interferon-τ in relapsing-remitting multiple sclerosis
    Olek, MJ
    Smith, DR
    Cook, SL
    Khoury, SJ
    Weiner, HL
    NEUROLOGY, 2001, 56 (08) : A76 - A76
  • [45] Hepatic safety of ozanimod in relapsing multiple sclerosis in the DAYBREAK open-label extension study
    Selmaj, K.
    Steinman, L.
    Comi, G.
    Bar-Or, A.
    Hartung, H. -P.
    Montalban, X.
    Havrdova, E. K.
    Sheffield, J. K.
    Minton, N.
    Afsari, S.
    Shi, F.
    Kappos, L.
    Cohen, J. A.
    Cree, B. A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 608 - 609
  • [46] Assessment of Effect of Vidofludimus Calcium on MS Progression in the Blinded Treatment and Open-Label Extension Periods of the Phase 2 Study (EMPhASIS) in Relapsing-Remitting Multiple Sclerosis
    Fox, R.
    Wolf, C.
    Muehler, A.
    Ondrus, M.
    Sciacca, V.
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 49 - 49
  • [47] Safety and tolerability of BG-12 in patients with relapsing-remitting multiple sclerosis: results from the phase 3 CONFIRM (Comparator and an Oral Fumarate in Relapsing-Remitting Multiple Sclerosis) study
    Havrdova, E.
    Phillips, J. T.
    Fox, R. J.
    Miller, D.
    Kita, M.
    Hutchinson, M.
    Raghupathi, K.
    Yuan, H.
    Novas, M.
    Sweetser, M. T.
    Viglietta, V.
    Dawson, K. T.
    JOURNAL OF NEUROLOGY, 2012, 259 : S105 - S105
  • [48] Vitamin D treatment of relapsing-remitting multiple sclerosis (RRMS): A MRI-based pilot study
    Fleming, JO
    Hummel, AL
    Beinlich, BR
    Borowski, BJ
    Peebles, T
    Colburn, M
    Cook, TD
    Wendt, GJ
    DeLuca, HF
    NEUROLOGY, 2000, 54 (07) : A338 - A338
  • [49] The relationship between MRI lesion activity, relapse count and disability progression in relapsing-remitting multiple sclerosis (RRMS)
    Sandberg-Wollheim, M
    King, J
    Pollard, J
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2005, 238 : S245 - S245
  • [50] Regulatory Cell Populations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients: Effect of Disease Activity and Treatment Regimens
    Rodi, Maria
    Dimisianos, Nikolaos
    de Lastic, Anne-Lise
    Sakellaraki, Panagiota
    Deraos, George
    Matsoukas, John
    Papathanasopoulos, Panagiotis
    Mouzaki, Athanasia
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (09)
12345